Examples of using Dapsone in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Drugs, such as dapsone, indomethacin, and interferons.
Alternative medications for skin disease include dapsone and retinoic acid Retin-A.
Dapsone, to prevent pneumonia and treat skin infections.
These include substances such as: clozapine,cimetidine, dapsone and loratadine.
Dapsone, or something like that, you have to take it for a while.
Have substantially delayed the progress of the disease. Dapsone, rifampicin and clofazimine.
Dapsone, rifampicin and clofazimine have substantially delayed the progress of the disease.
Ome medicines used to treat microbial infections(such as telithromycin,rifampicin, dapsone);
Dapsone is an odorless white to creamy-white crystalline powder with a slightly bitter taste.
He has a wonderful story of talking to a villager in India andsaying,"Have you taken your Dapsone?""Yes.
Certain medicines for infection- such as clarithromycin, dapsone, erythromycin, halofantrine, pentamidine, sparfloxacin.
In vitro the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine,cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethindrone, quinidine, tamoxifen,(triacetyl)oleandomycin.
More details Dapsone(Dapsone) Dapsone(Dapsone) is used to treat a skin condition known as dermatitis herpetiformis, and Hansen's disease, more commonly known as leprosy.
Influence of enfuvirtide on metabolism of concomitant medicinal products: In an in-vivo human metabolism study enfuvirtide, at the recommended dose of 90 mg twice daily,did not inhibit the metabolism of substrates by CYP3A4(dapsone), CYP2D6(debrisoquine), CYP1A2(caffeine), CYP2C19(mephenytoin), and CYP2E1 chlorzoxazone.
Methylthioninium chloride Proveblue can exacerbate dapsone-induced haemolytic anemia because of the formation of the dapsone reactive metabolite hydroxylamine which oxidises haemoglobin.
Methaemoglobinaemia may be accentuated in patients already taking medicinal products known to induce the condition, e.g. sulphonamides, acetanilid, aniline dyes, benzocaine,chloroquine, dapsone, metoclopramide, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenobarbital, phenytoin, primaquine and quinine see section 4.4.
If your blood disorder has been caused by a medicine called dapsone(used to treat leprosy and other skin conditions); lower doses may be needed and total cumulative dose should not exceed 4 mg/kg see section 3.
Administration of Pegasys 180 micrograms once weekly for 4 weeks in healthy male subjects did not show any effect on mephenytoin, dapsone, debrisoquine and tolbutamide pharmacokinetics profiles, suggesting that Pegasys has no effect on in vivo metabolic activity of cytochrome P450 3A4, 2C9, 2C19 and 2D6 isozymes.
Phenytoin, probenecid, rifampicin, atovaquone, valproic acid,methadone, dapsone, pentamidine, pyrimethamine, co-trimoxazole, fluconazole, amphotericin, flucytosine, ganciclovir, interferon, clarithromycin, vincristine, vinblastine and doxorubicin.
A clinically significant pharmacokinetic interaction was not observed between peginterferon alfa-2b(ViraferonPeg) and tolbutamide,midazolam or dapsone; therefore, no dosing adjustment is necessary when peginterferon alfa-2b(ViraferonPeg) is administered with medicines metabolized by CYP2C9, CYP3A4 and N-acetyltransferase.
Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive medicinal products(e. g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also increase the risk of adverse reactions to zidovudine.
Concomitant treatment, especially acute therapy, with potentially nephrotoxic ormyelosuppressive medicinal products(e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also increase the risk of adverse reactions to zidovudine.
Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive medicinal products(e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also increase the risk of adverse reactions to zidovudine see section 4.8.